Enzymes of the AKR1B and AKR1C subfamilies and uterine diseases

Frontiers in Pharmacology

Volumn 3 MAR, Issue , 2012, Pages

  Rižner, Tea Lanišnik ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cervical cancer; Endometrial cancer; Endometriosis; Estrogens; Prostaglandins; Retinoids; Uterine myoma

Indexed keywords

17 HYDROXYSTEROID DEHYDROGENASE; 20 OXOSTEROID REDUCTASE; ALDO KETO REDUCTASE 1B1; ALDO KETO REDUCTASE 1B10; ALDO KETO REDUCTASE 1C; ALDO KETO REDUCTASE 1C1; ALDO KETO REDUCTASE 1C2; ALDO KETO REDUCTASE 1C3; ALDO KETO REDUCTASE 1C4; CISPLATIN; DAUNORUBICIN; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN F2 ALPHA; RETINOIC ACID; RETINOL; STEROID REDUCTASE; UNCLASSIFIED DRUG;

AKR1B GENE; AKR1C1 GENE; AKR1C2 GENE; AKR1C3 GENE; ARTICLE; CANCER PATIENT; CATALYSIS; CELL PROLIFERATION; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; UTERINE CERVIX CANCER; UTERUS MYOMA;

EID: 84865968660     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00034     Document Type: Article

References (96)

1. Abu, J., Batuwangala, M., Herbert, K., and Symonds, P. (2005). Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer. Lancet Oncol. 6, 712-720.
2. Alexiou, P., Pegklidou, K., Chatzopoulou, M., Nicolaou, I., and Demopoulos, V. J. (2009). Aldose reductase enzyme and its implication to major health problems of the 21st century. Curr. Med. Chem. 16, 734-752.
3. Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., and Vergote, I. (2005). Endometrial cancer. Lancet 366, 491-505.
4. Andersson, S., Minjarez, D., Yost, N. P., and Word, R. A. (2008). Estrogen and progesterone metabolism in the cervix during pregnancy and parturition. J. Clin. Endocrinol. Metab. 93, 2366-2374.
5. Banu, S. K., Starzinski-Powitz, A., Speights, V. O., Burghardt, R. C., and Arosh, J. A. (2009). Induction of peritoneal endometriosis in nudemice with use of human immortalized endometriosis epithelial and stromal cells: a potential experimental tool to study molecular pathogenesis of endometriosis in humans. Fertil. Steril. 91, 2199-2209.
6. Barski, O. A., Tipparaju, S. M., and Bhatnagar, A. (2008). The aldoketo reductase superfamily and its role in drug metabolism and detoxification. Drug Metab. Rev. 40, 553-624.
7. Beranič, N., Brožic, P., Brus, B., Sosic, I., Gobec, S., and Lanišnik Rižner, T. (2012). Expression of human aldoketo reductase 1C2 in cell lines of peritoneal endometriosis: potential implications in metabolism of progesterone and dydrogesterone and inhibition by progestins. J. Steroid. Biochem. Mol. Biol. 130, 16-25.
8. Beranič, N., Gobec, S., and Lanišnik Rižner, T. (2011). Progestins as inhibitors of the human 20ketosteroid reductases, AKR1C1 and AKR1C3. Chem. Biol. Interact. 191, 227-233.
9. Berkley, K. J., Rapkin,A. J., and Papka, R. E. (2005). The pains of endometriosis. Science 308, 1587-1589.
10. Berndt, N., Hamilton, A. D., and Sebti, S. M. (2011). Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11, 775-791.
11. Bresson, E., Boucher-Kovalik, S., Chapdelaine, P., Madore, E., Harvey, N., Laberge, P. Y. L., Leboeuf, M., and Fortier, M. A. (2011). The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium. J. Clin. Endocrinol. Metab. 96, 210-219.
12. Brožic, P., Turk, S., Lanišnik Rižner, T., and Gobec, S. (2011). Inhibitors of aldo-keto reductases AKR1C1AKR1C4. Curr. Med. Chem. 18, 2554-2565.
13. Bulun, S. E. (2009). Endometriosis. N. Engl.J.Med.360, 268-279.
14. Byrns, M. C., Duan, L., Lee, S. H., Blair, I. A., and Penning, T. M. (2010). Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its overexpression in breast cancer. J. Steroid Biochem. Mol. Biol. 118, 177-187.
15. Byrns, M. C., Jin, Y., and Penning, T. M. (2011). Inhibitors of type 5 17α-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. J. Steroid Biochem. Mol. Biol. 125, 95-104.
16. Byrns, M. C., and Penning, T. M. (2007). " Selective inhibitors of AKR1C3 as anti-proliferative agents," in Enyzmology and Molecular Biology of Carbonyl Metabolism, eds H. Weiner, E. Maser, R. Lindahl, and B. Plapp (West Lafayette: Purdue University Press), 242-251.
17. Carter, C. A. (2003). Retinoic acid signaling through PI-3-kinase induces differentiation of human endometrial adenocarcinoma cells. Exp. Mol. Pathol. 75, 34-44.
18. Catalano, R. D.,Wilson, M. R., Boddy, S. C., and Jabbour, H. N. (2011). Comprehensive expression analysis of prostanoid enzymes and receptors in the human endometrium across the menstrual cycle. Mol. Hum. Reprod. 17, 182-192.
19. Chapdelaine, P., Kang, J., BoucherKovalik, S., Caron, N., Tremblay, J. P., and Fortier, M. A. (2006). Decidualization and maintenance of a functional prostaglandin system in human endometrial cell lines following transformation with SV40 large T antigen. Mol. Hum. Reprod. 12, 309-319.
20. Cheng, Y. H., Utsunomiya, H., Pavone, M. E., Yin,P., and Bulun, S. E. (2011). Retinoic acid inhibits endometrial cancer growth via multiple genomic mechanisms. J. Mol. Endocrinol. 46, 139-153.
21. Chung, S. H., Franceschi, S., and Lambert, P. H. (2010). Estrogen and Era: culprits in cervical cancer? Trends Endocrinol. Metab. 21, 504-511.
22. Digits, J. A., Pyun, H. J., Coates, R. M., and Casey, P. J. (2002). Stereospecificity and kinetic mechanism of human prenylcysteine lyase, an unusal thioether oxidase. J. Biol. Chem. 277, 41086-41093.
23. Dozier, B. L., Watanabe, K., and Duffy, D. M. (2008). Two pathways for prostaglandin F2α synthesis by the primate periovulatory follicle. Reproduction 136, 53-63.
24. Endo, S., Matsunaga, T., Ohta, C., Soda, M., Kanamori, A., Kitade, Y., Ohno, S., Tajima, K., El-Kabbani, O., and Hara, A. (2011). Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol. Chem. Biol. Interact. 191, 261-268.
25. Endo, S., Matsunaga, T., Soda, M., Tajima, K., Zhao, H. T., El-Kabbani, O., and Hara, A. (2010). Selective inhibition of the tumor marker AKR1B10 by antiinflammatory Nphenylanthranilic acids and glycyrrhetic acid. Biol. Pharm. Bull. 33, 886-890.
26. Faridi, R., Zahra, A., Khan, K., and Idrees, M. (2011). Oncogenic potential of human papillomavirus (HPV) and its relation with cerical cancer. Virol. J. 8, 269.
27. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers. C., and Parkin, D. M. (2008). GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr, accessed on 25/10/2011
28. Fukumoto, S.,Yamauchi, N., Moriguchi, H., Hippo, Y., Watanabe, A., Shibahara, J., Taniguchi, H., Ishikawa, S., Ito, H., Yamamoto, S., Iwanari, H., Hironaka, M., Ishikawa, Y., Niki, T., Sohara, Y., Kodama, T., Nishimura, M., Fukayama, M., Dosaka-Akita, H., and Aburatani, H. (2005). Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers'nonsmall cell lung carcinomas. Clin. Cancer Res. 11, 1776-1785.
29. Giudice, L. C., and Kao, L. C. (2004). Endometriosis. Lancet 364, 1789-1799.
30. Goss, P. E., Shangle, Q., Hu, H., Gediya, L. K., Purushottamachar, P., Godbole, A. M., and Njar, V. C. O. (2011). Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-Nnitrosourea-induced rat mammary carcinoma model and its effects on the uterus. Breast Cancer Res. Treat. (in press).
31. Herfs, M., Herman, L., Hubert, P., Minner, F., Arafa, M., Roncarati, P., Henroitin, Y., Boniver, J., and Delvenne, P. (2009). High expression of PGE2 enzymatic pathway in cervical (pre)neoplastic lesions and functional consequences for antigenpresenting cells. Cancer Immunol. Immunother. 58, 603-614.
32. Hevir, N., Vouk, K., Šinkovec, J., RibicPucelj, M., and Lanišnik Rižner, T. (2011). Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. Chem. Biol. Interact. 191, 217-226.
33. Higaki, Y., Usami, N., Shintani, S., Ishikura, S., El-Kabbani, O., and Hara, A. (2003). Selective and potent inhibitors of human 20αhydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem. Biol. Interact. 143/144, 503-513.
34. Hompes, P. G., and Mijatovic, V. (2007). Endometrisis: the way forward. Gynecol. Endocrinol. 23, 5-12.
35. Huang, K. H., Chiou, S. H., Chow, K. C., Lin, T. Y., Chang, H. W., Chiang, I. P., and Lee, M. C. (2010). Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer. Histopathology 57, 384-394.
36. Inoue, M. (2001). Current molecular aspects of the carcinogenesis of the uterine endometrium. Int. J. Gynecol. Cancer 11, 339-348.
37. Ito, K., Utsunomiya, H., Suzuki, T., Saitou, S., Akahira, J., Okamura, K., Yaegashi, N., and Sasano, H. (2006). 17beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol. Cell. Endocrinol. 248, 136-140.
38. Jabbour, H. N., Sales, K. J., Milling Smith,O. P., Battersby, S., and Boddy, S. C. (2006). Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol. Cell. Endocrinol. 252, 191-200.
39. Kabututu, Z., Manin, M., Pointud, J. C., Maruyama, T., Nagata, N., Lambert, S., Lefrancois-Martinez, A. M., Martinez, A., and Urade, Y. (2009). Prostaglandin F2α synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7. J. Biochem. 145, 161-168.
40. Lanišnik Rižner, T., Šmuc, T., Rupreht, R., Šinkovec, J., and Penning, T. M. (2006). AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol. Cell. Endocrinol. 248, 126-135.
41. Le Calve, B., Rynkowski, M., Le Mercier, M., Bruyere, C., Lonez, C., Gras, T., Haibe-Kains, B., Bontempi, G., Decaestecker, C., Ruysschaert, J. M., Kiss, R., and Lefranc, F. (2010). Long-term in-vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia 12, 727-739.
42. Lee, R. H., Stanczyk, F. Z., Stolz, A., Ji, Q., Yang, G., and Goodwin, T. M. (2008). AKR1C1 and SRD5A1 messenger RNA expression at term in the human myometrium and chorioamniotic membranes. Am. J. Perinatol. 25, 577-582.
43. Lin, H. K., Steckelbroeck, S., Fung, K. M., Jones, A. M., and Penning, T. M. (2004). Characterization of a monoclaonal antibody for human aldoketo reductase AKR1C3 (type 2 3αhydroxysteroid dehydrogenase/type 517α-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69, 795-801.
44. Liu, J., Wen, G., and Cao, D. (2009). Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives. Recent Pat. Anticancer Drug Discov. 4, 256-253.
45. Liu, Z., Yan, R., Al-saman, A., Shen, Y., Bu, Y., Ma, J., Luo, D. X., Huang, C., Jiang,Y.,Wilber,A., Mo,Y. Y., Huang, M. C., Zhao, Y., and Cao, D. (2011). Epidermal growth factor induces tumor marker AKR1B10 expression through activator protein-1 signaling in hepatocelluar carcinoma cells. Biochem. J. (in press).
46. Lousse, J. C., Defrere, S., Collete, S., Van Langendonckt, A., and Donnez, J. (2010). Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis. Hum Reprod. 25, 734-741.
47. Luo, D., Huang, M. C., Ma, J., Gao, Z., Liao, D. F., and Cao, D. (2011). Aldo-keto reductase family 1, member B10 is secreted through a lysosome-mediated non-classical pathway. Biochem. J. 438, 71-80.
48. Matsunaga, T., Wada, Y., Endo, S., Soda, M., El-Kabbani, O., Hara, A. (2012) Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers. Front. Pharmacol. doi:10.3389/fphar.2012.00005. (in press).
49. Matsuura, K., Shiraishi, H., Hara, A., Sato, K., Deyashiki, Y., Ninomiya, M., and Sakai, S. (1998). Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J. Biochem. 124, 940-946.
50. Maybin, J. A., Critchley, H. O. D., and Jabbour, H. N. (2011). Inflammatroy pathways in endometrial disorders. Mol. Cell. Endocrinol. 335, 42-51.
51. Miller, C. E. (2008). Unmet therapeutic need for uterine myomas. J. Minim. Invasive Gynecol. 16, 11-21.
52. Myga-Nowak, M., Pacholska-Bogalska, J., Kwasniewski, W., Kwasniewska, A., and Gozdzicka-Jozefiak, A. (2011). Proliferation of cells and expression of RARs, RXRs and HPV viral E6 and E7 proteins in cervical cancer cell lines after treatment with ATRA. Ann. Agric. Environ. Med. 18, 145-150.
53. Nagata, N., Kusakari, Y., Fukunishi, Y., Inoue, T., and Urade, Y. (2011). Catalytic mechanism of the primary human prostaglandin F2α synthase, aldo-keto reductase 1B1prostaglandin D2 synthase activity in the absence of NADP(H). FEBS J. 278, 1288-1298.
54. Nakajima, T., Yasuda, K., Nishizawa, M., Okada, H., Yoshimura, T., Ito, S., and Kanzaki, H. (2003). Expression of 20α-hydroxysteroid dehydrogenase mRNA in human endometrioum and decidua. Endocr. J. 50, 105-111.
55. Nishizawa, M., Nakajima, T., Yasuda, K., Kanzaki, H., Sasaguri, Y., Watanabe, K., and Ito, S. (2000). Close kinship of human 20a-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells 5, 111-125.
56. Nisolle, M., and Donnez, J. (1997). Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil. Steril. 68, 585-596.
57. Novelli, G., D'Apice, M. R. (2012). Protein farnesylation and disease. J. Inherit. Metab. Dis. doi:10.1007/s10545-011-9445-y. (in press).
58. Pavone, M. E., Dyson, M., Reirstad, S., Pearson, E., Ishikawa, H., Cheng, Y. H., and Bulun, S. E. (2011). Endometriosis expresses a molecular pattern consistent with decreased retinol uptake, metabolism and action. Hum. Reprod. 26, 2157-2164.
59. Pelletier, G., Luu-The, V., Tetu, B., and Labrie, F. (1999). Immunoytochemical localization of type 517β-hydroxyseroid dehydrogeanse in human reproductive tissues. J. Histochem. Cytochem. 47, 731-737.
60. Penning, T. (2005). AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin. Cancer Res. 11, 1687-1690.
61. Penning, T. M., Burczynski, M. E., Jez, J. M., Hung, C. F., Lin, H. K., Ma, H., Moore, M., Palackal, N., and Ratnam, K. (2000). Human 3αhydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351, 67-77.
62. Penning, T. M., and Drury, J. E. (2007). Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphism. Arch. Biochem. Biophys. 464, 241-250.
63. Phillips, R. J., Al-Zamil, H., Hunt, L. P., Fortier, M. A., and Bernal, A. L. (2011). Genes for prostaglandin synthesis, transport and inactivation are differentially expressed in human uterine tissues, and the prostaglandin F synthase AKR1B1 is induced in myometrial cells by inflammatory cytokines. Mol. Hum. Reprod.17, 1-13.
64. Ramana, K. V. (2011). Aldose reductase: new insights for an old enzyme. Biomol. Concepts 2, 103-114.
65. Roberson, A. E., Hyatt, K., Kenkel, C., Hanson, K., and Myers, A. A. (2011). Interleukin 1b regulates progesterone metabolism in human cervical fibroblasts. Reprod. Sci. (in press).
66. Rossi, M., Sharkey, A. M., Vigano, P., Fiore, G., Furlong, R., Florio, P., Ambrosini, G., Smith, S. K., and Petragli, F. (2005). Identification of genes regulated by interleukin-1b in human endometrial stromal cells. Reproduction 130, 721-729.
67. Ruiz, F. X., Moro, A., Gallego, O., Ardevol, A., Rovira, C., Petrash, J. M., Pares, X., and Farres, J. (2011a). Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde. Chem. Biol. Interact. 191, 199-205.
68. Ruiz, F. X., Porte, S., Gallego, O., Moro, A., Ardevol, A., Del Rio-Espinola, A., Rovira, C., Farres, J., and Pares, X. (2011b). Retinaldehyde is a substrate for human aldo-keto reductase of the 1C subfamily. Biochem. J. 440, 335-344.
69. Ryan, A. J., Susil, B., Jobling, T. W., and Oehler, M. K. (2005). Endometrial cancer. Cell Tissue Res. 322, 53-61.
70. Sales, K. J., Boddy, S. C., Williams, A. R. W., Anderson, R. A., and Jabbour, H. N. (2007). F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 148, 3635-3644.
71. Sales, K. J., Grant,V., and activate the FP receptor andαJabbour, H. N. (2008). Prostaglandin E2 and F2 up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Mol. Cell. Endocrinol. 285, 51-61.
72. Sales, K. J., List, T., Boddy, S. C., Williams, A. R. W., Anderson, R. A., Naor, Z., and Jabbour, H. N. (2005). A novel angiogenic role for prostaglandin F2α-FP receptor interaction in human endometrial adenocarcinoma. Cancer Res. 65, 7707-7716.
73. Saraswat, M., Mrudula, T., Kumar, P. U., Suneetha, A., Rao, T. S., Srinivasulu, M., and Reddy, G. B. (2006). Overexpression of aldose reductase in human cancer tissues. Med. Sci. Monit. 12, CR525-CR529.
74. Sharma, K. K., Lindqvist, A., Zhou, X. J., Auchus, R. J., Penning, T. M., and Andersson, S. (2006). Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues. Mol. Cell. Endocrinol. 248, 79-86.
75. Shen, Y., Zhong, L., Johnson, S., and Cao, D. (2011). Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. Chem. Biol. Interact. 191, 192-198.
76. Šmuc, T., Hevir, N., Ribic-Pucelj, M., Husen, B., Thole, H., and Lanišnik Rižner, T. (2009). Disturbed estrogen and progesterone action in ovarian endometriosis. Mol. Cell. Endocrinol. 301, 59-64.
77. Šmuc, T., and Lanišnik Rižner, T. (2009). Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol. Cell. Endocrinol. 301, 74-82.
78. Soda, M., Hu, D., Endo, S., Takemura, M., Li, J., Wada, R., Ifuku, S., Zhao, H. T.,El-Kabbani,O.,Ohta,S.,Yamamura, K., Toyooka, N., Hara, A., Matsunaga, T. (2012). Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10. Eur. J. Med. Chem. 48, 321-329.
79. Srivastava, S. K., Yadav, U. C., Reddy, A. B., Saxena, A., Tammali, R., Shoeb, M., Ansari, N. H., Bhatnagar, A., Petrash, M. J., Srivastava, S., and Ramana, K. V. (2011). Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem. Biol. Interact. 191, 330-338.
80. Steckelbroeck, S., Jin, Y., Gopishetty, S., Oyesanmi, B., and Penning, T. M. (2004). Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity:implications for steroid hormone metabolism and action. J. Biol. Chem. 279, 10784-10795.
81. Takemura, M., Endo, S., Matsunaga, T., Soda, M., Zhao, H. T., El-Kabbani, O., Tajima, K., Iinuma, M., and Hara, A. (2011). Selective inhibition of the tumor marker aldoketo reductase family member 1B10 by oleanolic acid. J. Nat. Prod. 74, 1201-1206.
82. Tammali, R., Srivastava, S. K., and Ramana, K. V. (2011). Targeting aldose redutase for the treatment of cancer. Curr. Cancer Drug Targets 11, 560-571.
83. Tanabe, K., Utsunomiya, H., Tamura, M., Niikura, H., Takano, T., Yoshinaga, K., Nagase, S., Suzuki, T., Ito, K., Matsumoto, M., Hayashi, S., and Yaegashi, N. (2008). Expression of retinoic acid receptors in human endometrialc carcinoma. Cancer Sci. 99, 267-271.
84. Ueda, M., Hung, Y. C., Chen, J. T., Chiou, S. H., Huang, H. H., Lin, T. Y., Terai, Y., and Chow, K. C. (2006). Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. Gynecol. Oncol. 102, 173-181.
85. Usami, N., Yamamoti, T., Shintani, S., Higaki, Y., Ishikura, S., Katagiri, Y., and Hara, A. (2002). Substrate specificity of human 3(20)αhydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol. Pharm. Bull. 25, 441-445.
86. Wallace, A. E., Gibson, D. A., Saunders, P. T. K., and Jabbour, H. N. (2010). Inflammatory events in endometrial adenocarcinoma. J. Endocrinol. 206, 141-157.
87. Wang, C., Yan, R., Luo, D., Watabe, K., Liao, D. F., and Cao, D. (2009). Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J. Biol. Chem. 284, 26742-26748.
88. Wanichwatanadecha, P., Sirisrimangkorn, S., Kaewprag, J., and Ponglikitmongkol, M. (2012). Transactivation activity of human papillomavirus type 16 E16*I on AKR1C enhances chemoresistance in cervical cancer cells. J. Gen. Virol. (in press).
89. Wiebe, J. P. (2006). Progesterone metabolites in breast cancer. Endocr. Relat. Cancer 13, 717-738.
90. Wu, M. H. (2005). Suppression of matrix metaloproteinase-9 by prostaglandin E2 in peritoneal macrophages is associated with severity of endometriosis. Am. J. Pathol. 167, 1061-1069.
91. Wu, M. H., Lu, C.W., Chuang, P. -C., and Tsai, S. -J. (2010). Prostaglandin E2: the master of endometriosis? Exp. Biol. Med. 235, 668-677.
92. Wu, M. H., Shoji, Y., Chuand, P. C., and Tsai, S. J. (2007). Endometriosis: disease pathophysiology and the role of prostaglandins. Expert. Rev. Molec. Med. 9, 1-19.
93. Yoshitake, H., Takahashi, M., Ishikawa, H., Nojima, M., Iwanaris, H., Watanabe, A., Aburatani, H., Yoshida, K., Ishi, K., Takamori, K., Ogawa, H., Hamakubo, T., Kodama, T., and Araki,Y. (2007). Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int. J. Gynecol. Cancer 17, 1300-1306.
94. Zaitseva, M., Vollenhoven, B. J., and Rogers, P. A. W. (2007). Retinoic acid pathway genes show significantly altered expression in uterine fibroids when compared with normal endometrium. Mol. Hum. Reprod. 13, 577-585.
95. Zakhaorov, V., Lin, H. K., Azzarello, J., McMeekin, S., Moore, K. N., Penning, T. M., and Fung, K. M. (2010). Suppressed expression of type23α/type517β-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int. J. Clin. Exp. Pathol. 3, 608-617.
96. Zhong, L., Shen, H., Huang, C., Jing, H., and Cao, D. (2011). AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol. Appl. Pharmacol. 255, 40-47.